All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Visual abstract | Apremilast in patients with plaque psoriasis
By Alice Hyde
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing key data from the phase III ADVANCE trial (NCT03721172), which investigated the efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis.1 This double blind, placebo-controlled trial investigated systemic apremilast in 595 patients with mild-to-moderate plaque psoriasis that was inadequately controlled or intolerant to ≥1 topical psoriasis agent.1
Apremilast is already used to treat patients with moderate-to-severe plaque psoriasis that has not responded to standard systemic treatment or photochemotherapy and is approved by the European Medicines Agency (EMA)2 and the National Institute for Health and Care Excellence (NICE)3.
More recently, apremilast received U.S Food and Drug Administration (FDA) approval in December 2021 for treatment of all patients with plaque psoriasis, making it the only oral agent that works across all severities.4
- Stein Gold L, Papp K, Pariser, et al. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86(1):77-85. DOI: 1016/j.jaad.2021.07.040
- European Medicines Agency. Otezla. https://www.ema.europa.eu/en/medicines/human/EPAR/otezla. Published Feb 16, 2015. Accessed May 5, 2022.
- FDA approves Amgen’s Otezla for all patients with plaque psoriasis. https://www.pmlive.com/pharma_news/fda_approves_amgens_otezla_for_all_patients_with_plaque_psoriasis_1385707. Published Dec 22, 2021. Accessed May 4, 2022.
- PR Newswire. FDA approves Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis, regardless of severity level. https://www.prnewswire.com/news-releases/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level-301448542.html. Published Dec 2021. Accessed May 9, 2022.
Your opinion matters
6 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox